Cargando…

Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring

BACKGROUND: Mycobacterium ulcerans, the causative agent of Buruli ulcer (BU), is unique among human pathogens in its capacity to produce a polyketide-derived macrolide called mycolactone, making this molecule an attractive candidate target for diagnosis and disease monitoring. Whether mycolactone di...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarfo, Fred S., Le Chevalier, Fabien, Aka, N'Guetta, Phillips, Richard O., Amoako, Yaw, Boneca, Ivo G., Lenormand, Pascal, Dosso, Mireille, Wansbrough-Jones, Mark, Veyron-Churlet, Romain, Guenin-Macé, Laure, Demangel, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139662/
https://www.ncbi.nlm.nih.gov/pubmed/21811642
http://dx.doi.org/10.1371/journal.pntd.0001237
_version_ 1782208488668135424
author Sarfo, Fred S.
Le Chevalier, Fabien
Aka, N'Guetta
Phillips, Richard O.
Amoako, Yaw
Boneca, Ivo G.
Lenormand, Pascal
Dosso, Mireille
Wansbrough-Jones, Mark
Veyron-Churlet, Romain
Guenin-Macé, Laure
Demangel, Caroline
author_facet Sarfo, Fred S.
Le Chevalier, Fabien
Aka, N'Guetta
Phillips, Richard O.
Amoako, Yaw
Boneca, Ivo G.
Lenormand, Pascal
Dosso, Mireille
Wansbrough-Jones, Mark
Veyron-Churlet, Romain
Guenin-Macé, Laure
Demangel, Caroline
author_sort Sarfo, Fred S.
collection PubMed
description BACKGROUND: Mycobacterium ulcerans, the causative agent of Buruli ulcer (BU), is unique among human pathogens in its capacity to produce a polyketide-derived macrolide called mycolactone, making this molecule an attractive candidate target for diagnosis and disease monitoring. Whether mycolactone diffuses from ulcerated lesions in clinically accessible samples and is modulated by antibiotic therapy remained to be established. METHODOLOGY/PRINCIPAL FINDING: Peripheral blood and ulcer exudates were sampled from patients at various stages of antibiotic therapy in Ghana and Ivory Coast. Total lipids were extracted from serum, white cell pellets and ulcer exudates with organic solvents. The presence of mycolactone in these extracts was then analyzed by a recently published, field-friendly method using thin layer chromatography and fluorescence detection. This approach did not allow us to detect mycolactone accurately, because of a high background due to co-extracted human lipids. We thus used a previously established approach based on high performance liquid chromatography coupled to mass spectrometry. By this means, we could identify structurally intact mycolactone in ulcer exudates and serum of patients, and evaluate the impact of antibiotic treatment on the concentration of mycolactone. CONCLUSIONS/SIGNIFICANCE: Our study provides the proof of concept that assays based on mycolactone detection in serum and ulcer exudates can form the basis of BU diagnostic tests. However, the identification of mycolactone required a technology that is not compatible with field conditions and point-of-care assays for mycolactone detection remain to be worked out. Notably, we found mycolactone in ulcer exudates harvested at the end of antibiotic therapy, suggesting that the toxin is eliminated by BU patients at a slow rate. Our results also indicated that mycolactone titres in the serum may reflect a positive response to antibiotics, a possibility that it will be interesting to examine further through longitudinal studies.
format Online
Article
Text
id pubmed-3139662
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31396622011-08-02 Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring Sarfo, Fred S. Le Chevalier, Fabien Aka, N'Guetta Phillips, Richard O. Amoako, Yaw Boneca, Ivo G. Lenormand, Pascal Dosso, Mireille Wansbrough-Jones, Mark Veyron-Churlet, Romain Guenin-Macé, Laure Demangel, Caroline PLoS Negl Trop Dis Research Article BACKGROUND: Mycobacterium ulcerans, the causative agent of Buruli ulcer (BU), is unique among human pathogens in its capacity to produce a polyketide-derived macrolide called mycolactone, making this molecule an attractive candidate target for diagnosis and disease monitoring. Whether mycolactone diffuses from ulcerated lesions in clinically accessible samples and is modulated by antibiotic therapy remained to be established. METHODOLOGY/PRINCIPAL FINDING: Peripheral blood and ulcer exudates were sampled from patients at various stages of antibiotic therapy in Ghana and Ivory Coast. Total lipids were extracted from serum, white cell pellets and ulcer exudates with organic solvents. The presence of mycolactone in these extracts was then analyzed by a recently published, field-friendly method using thin layer chromatography and fluorescence detection. This approach did not allow us to detect mycolactone accurately, because of a high background due to co-extracted human lipids. We thus used a previously established approach based on high performance liquid chromatography coupled to mass spectrometry. By this means, we could identify structurally intact mycolactone in ulcer exudates and serum of patients, and evaluate the impact of antibiotic treatment on the concentration of mycolactone. CONCLUSIONS/SIGNIFICANCE: Our study provides the proof of concept that assays based on mycolactone detection in serum and ulcer exudates can form the basis of BU diagnostic tests. However, the identification of mycolactone required a technology that is not compatible with field conditions and point-of-care assays for mycolactone detection remain to be worked out. Notably, we found mycolactone in ulcer exudates harvested at the end of antibiotic therapy, suggesting that the toxin is eliminated by BU patients at a slow rate. Our results also indicated that mycolactone titres in the serum may reflect a positive response to antibiotics, a possibility that it will be interesting to examine further through longitudinal studies. Public Library of Science 2011-07-19 /pmc/articles/PMC3139662/ /pubmed/21811642 http://dx.doi.org/10.1371/journal.pntd.0001237 Text en Sarfo et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Sarfo, Fred S.
Le Chevalier, Fabien
Aka, N'Guetta
Phillips, Richard O.
Amoako, Yaw
Boneca, Ivo G.
Lenormand, Pascal
Dosso, Mireille
Wansbrough-Jones, Mark
Veyron-Churlet, Romain
Guenin-Macé, Laure
Demangel, Caroline
Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring
title Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring
title_full Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring
title_fullStr Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring
title_full_unstemmed Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring
title_short Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring
title_sort mycolactone diffuses into the peripheral blood of buruli ulcer patients - implications for diagnosis and disease monitoring
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139662/
https://www.ncbi.nlm.nih.gov/pubmed/21811642
http://dx.doi.org/10.1371/journal.pntd.0001237
work_keys_str_mv AT sarfofreds mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring
AT lechevalierfabien mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring
AT akanguetta mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring
AT phillipsrichardo mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring
AT amoakoyaw mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring
AT bonecaivog mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring
AT lenormandpascal mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring
AT dossomireille mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring
AT wansbroughjonesmark mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring
AT veyronchurletromain mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring
AT gueninmacelaure mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring
AT demangelcaroline mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring